These findings were notable because most drugs used in type 2 diabetes have not been shown to improve cardiovascular outcomes. Accordingly, there is growing interest in empagliflozin and the entire SGLT2 inhibitor class as drugs that could potentially change the manner in which we approach the ...
Secondly, we determine the sufficient and necessary conditions for optimal control strategy of SGLT-2 inhibitors so as to avert side effects on normal cells using a Pontryagin's Minimum Principle. The results showed that if the ingestion rate of the inhibitor drug is equal to the digestion rate...
Type 2 DiabetesSGL2 InhibitorDehydrationGenitourinary InfectionSGLT2 inhibitors improve hyperglycemia with a decline in body weight and blood pressure, the outcomes touted to be of major importance in management of type 2 diabetes. However, the efficacy in lowering glycemia is very modest and imparts...
These findings were notable because most drugs used in type 2 diabetes have not been shown to improve cardiovascular outcomes. Accordingly, there is growing interest in empagliflozin and the entire SGLT2 inhibitor class as drugs that could potentially change the manner in which we approach the ...
advanced T2D, a moderate carb restricted diet may be okay while on an SGLT2 inhibitor. However, it would stand to reason that a very low carb diet could be dangerous. Also, most people on very low carb diets achieve great numbers with insulin alone. They probably don’t need SGLT2 ...
Other SGLT-2 inhibitors, such as dapagliflozin, ipragliflozin, empagliflozin, and ertugliflozin, can be used with metformin and sulphonal urea (SU) as a two-drug therapy. Starting this month, the insurance authorities also reimburse the three-drug therapy of metformin + SGLT-2 inhibitor + thiazo...
As described above, this study will be able to provide insights into the mechanism of the positive cardiovascular effects conferred by SGLT2 inhibitor therapy and may also help underpin future outcome trials in HF patients involving this drug class....
Metformin and SGLT2 inhibitors together reduce the blood sugar levels considerably more effectively than either drug alone. Scientists from the Helmholtz Zentrum München, partner in the German Center for Diabetes Research, report in the journal 'Diabete
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of gluco
Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is approve